中国医药品牌怎么样 申请店铺

我要投票 中国医药在化学药物行业中的票数:1021 更新时间:2026-01-30
中国医药是哪个国家的品牌?「中国医药」是 中国医药集团有限公司 旗下著名品牌。该品牌发源于北京市,由创始人佘鲁林在1987-03-26期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力中国医药品牌出海!将品牌入驻外推网,定制中国医药品牌推广信息,可以显著提高中国医药产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

中国医药怎么样

中国医药健康产业股份有限公司是在上海证券交易所挂牌的国有控股上市公司(股票简称:中国医药;证券代码:600056),其控股股东为中央骨干企业中国通用技术(集团)控股有限公司。公司秉承“关爱生命、追求卓越”的核心理念,致力于医药产业发展和人类健康事业,努力打造中国医药领域的旗舰企业。

公司已经建立起了以国际贸易为引领、以医药工业为支撑、以医药商业为纽带的科工贸一体化产业格局,产业形态涉及研发、种植加工、生产、分销、物流、进出口贸易、学术推广、技术服务等全产业链条。

在医药研发生产领域,公司拥有两家博士后科研工作站及一大批高素质研发专家,曾获国家科技进步二等奖;公司拥有国内领先的化学原料药研发生产平台,国内先进的特色化学药、现代中药研发生产平台,在抗感染类、抗病毒类药物的研发生产及甘草等药材及其制品的种植加工领域处于领先地位。

在国际贸易领域,作为医药行业进出口领域传统专业主渠道,公司始终保持着领先地位,且在政府项目业务领域具备传统实力和特色优势。天然药物贸易业务坚持全产业链专业化发展模式,有机整合天然药物种植、仓储、加工、销售等产业链环节,在行业内居于领先地位。医药化工贸易业务经营范围涵盖化学原料及制剂、生物及血液制品各品规、全领域,可为客户提供一流的医药化工贸易集成服务。医疗器械贸易业务致力于为客户提供全过程项目集成化服务,并与世界各著名医疗器械生产商建立了稳固的合作关系,在进口和分销领域处于国内领先地位。健康领域大宗商品业务涉及保健食品原料、大宗农产品、精细化工原材料等,在一些重点商品进出口贸易领域有较高知名度。

在国内医药商业领域,公司已逐步建立起以高端、特色产品为核心,具有产业价值链整合协同优势的医药商业体系。已形成以北京、广东、江西、河南、河北、湖北、新疆为重点,覆盖全国的营销网络体系,并在所在区域具有较高的知名度和品牌影响力。公司建有大型物流中心,具备完善的经营资质,可为广大合作伙伴提供全方位的增值服务。

面向未来,中国医药着力在重点产品领域建立横跨国内和国际两个市场的营销网络,聚焦现代中药、特色化学制剂和生物制药等核心产业领域,打造集研发、生产、销售、服务于一体的产业链,努力将公司发展成为一家在国内医药行业中具有重要地位、在国际市场具有较强竞争力和品牌影响力的科工贸一体化大型医药企业集团。



China Pharmaceutical and Health Industry Co., Ltd. is a state-owned holding listed company (stock abbreviation: China Pharmaceutical; securities code: 600056) listed on Shanghai Stock Exchange. Its controlling shareholder is China General Technology (Group) Holding Co., Ltd., a central backbone enterprise. Adhering to the core concept of "caring for life and pursuing excellence", the company is committed to the development of pharmaceutical industry and human health, striving to build a flagship enterprise in the field of Chinese medicine. The company has established an integrated industrial pattern of science, industry and trade with international trade as the guide, pharmaceutical industry as the support and pharmaceutical business as the link. The industrial pattern involves the whole industrial chain of R & D, planting and processing, production, distribution, logistics, import and export trade, academic promotion, technical services, etc. In the field of pharmaceutical R & D and production, the company has two postdoctoral research stations and a large number of high-quality R & D experts, who have won the second prize of national science and technology progress; the company has a leading R & D and production platform for chemical raw materials, domestic advanced characteristic chemical drugs, modern Chinese medicine research and development production platform, in the R & D and production of anti infective and anti viral drugs, licorice and other medicinal materials The planting and processing field of products is in a leading position. In the field of international trade, as the traditional professional main channel in the field of import and export of pharmaceutical industry, the company has always maintained a leading position, and has traditional strength and characteristic advantages in the field of government project business. The natural medicine trade business adheres to the whole industrial chain specialized development mode, organically integrates the natural medicine planting, storage, processing, sales and other industrial chain links, and takes the leading position in the industry. The business scope of pharmaceutical and chemical trade covers chemical raw materials and preparations, biological and blood products, and all fields. It can provide customers with first-class integrated pharmaceutical and chemical trade services. The medical device trade business is committed to providing customers with the whole process of project integration services, and has established a solid cooperative relationship with the world's famous medical device manufacturers, and is in the leading position in the field of import and distribution in China. The bulk commodity business in the health sector involves health food raw materials, bulk agricultural products, fine chemical raw materials, etc., and has a high reputation in the import and export trade of some key commodities. In the field of domestic pharmaceutical business, the company has gradually established a pharmaceutical business system with high-end, characteristic products as the core and industrial value chain integration and coordination advantages. It has formed a marketing network system focusing on Beijing, Guangdong, Jiangxi, Henan, Hebei, Hubei and Xinjiang, covering the whole country, and has a high visibility and brand influence in its region. The company has built a large-scale logistics center with perfect business qualification, which can provide all-round value-added services for the vast number of partners. Facing the future, China Pharmaceutical focuses on establishing a marketing network across the domestic and international markets in key product areas, focusing on core industries such as modern Chinese medicine, characteristic chemicals and biopharmaceuticals, creating an industrial chain integrating R & D, production, sales and service, and striving to develop the company into a company with an important position in the domestic pharmaceutical industry and in the international market A large pharmaceutical enterprise group with strong competitiveness and brand influence.

本文链接: https://brand.waitui.com/755334abf.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

原新加坡Sea AI Lab高级研究科学家庞天宇即将入职腾讯

36氪获悉,据相关消息证实,原新加坡Sea AI Lab高级研究科学家、清华大学计算机系2017级直博生庞天宇即将入职腾讯,加盟腾讯混元多模态部Exploration Center,负责强化学习前沿算法探索。

2小时前

伊戈尔向港交所提交上市申请书

36氪获悉,港交所文件显示,伊戈尔电气股份有限公司向港交所提交上市申请书,独家保荐人为国泰海通。

2小时前

韩国央行行长称对韩元大幅贬值感到困惑,呼吁养老基金进行外汇对冲操作

韩国央行行长李昌镛近日表示,韩元的贬值幅度远远超出了合理范围,并对这种贬值可能对通胀产生的影响表示担忧。周三,在高盛于香港举办的全球宏观研讨会上,李昌镛说:“如果回顾从去年11月开始的两个月,我确实感到很困惑,为何韩元的贬值幅度远远超出了我的预期。与美元指数相比,我们在10月和11月就开始出现脱钩了。”(新浪财经)

2小时前

集邦咨询:预估2026年全球AR眼镜出货量将跃升至95万台

36氪获悉,根据TrendForce集邦咨询最新近眼显示产业调查,随着AI与穿戴式装置深度融合,Meta Ray-Ban Display Glasses在终端市场获得的回馈明显优于预期,近半年内已大幅上修多项关键零部件订单。在大厂推波助澜之下,TrendForce集邦咨询预估2026年全球AR眼镜出货量将跃升至95万台,年增率为53%。

2小时前

星巴克计划2028财年全球净新增超2000家门店

星巴克当地时间1月29日发布声明称,目标2028财年全球自营和特许经营门店净新增超2000家,其中包括约400家美国自营门店;合并净收入增长5%或以上,全球和美国同店销售增长至少3%。(财联社)

2小时前

本页详细列出关于中国医药的品牌信息,含品牌所属公司介绍,中国医药所处行业的品牌地位及优势。
咨询